Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effects of chloroquine on viral infections: an old drug against today's diseases?

Andrea Savarino, Johan R Boelaert, Antonio Cassone, Giancarlo Majori, and Roberto Cauda.

Chloroquine is a 9-aminoquinoline known since 1934. Apart from its well-known antimalarial effects, the drug has interesting biochemical properties that might be applied against some viral infections. Chloroquine exerts direct antiviral effects, inhibiting pH-dependent steps of the replication of several viruses including members of the flaviviruses, retroviruses, and coronaviruses. Its best-studied effects are those against HIV replication, which are being tested in clinical trials. Moreover, chloroquine has immunomodulatory effects, suppressing the production/release of tumour necrosis factor α and interleukin 6, which mediate the inflammatory complications of several viral diseases. We review the available information on the effects of chloroquine on viral infections, raising the question of whether this old drug may experience a revival in the clinical management of viral diseases such as AIDS and severe acute respiratory syndrome, which afflict mankind in the era of globalisation.

**Lancet Infect Dis** 2003; 3: 722–27

Unfortunately, chloroquine is being gradually dismissed from antimalarial therapy and prophylaxis, due to the continuous emergence of chloroquine-resistant *Plasmodium falciparum* strains. However, the tolerability, low cost, and immunomodulatory properties of chloroquine/hydroxychloroquine have represented a valid contribution to the available pharmacological tools, since they proved able to slow down the progress of the disease while showing limited toxicity.

General biochemical and cellular effects of chloroquine

Both chloroquine and hydroxychloroquine are weak bases that are known to affect acid vesicles leading to dysfunction of several enzymes. Extracellularly, chloroquine/hydroxychloroquine is present mostly in a protonated form that, due to its positive charge, is incapable of crossing the plasma membrane. However, the non-protonated portion can enter the intracellular compartment, where, in turn, it becomes protonated in a manner inversely proportional to the pH, according to the Henderson-Hasselbach law. It is thus not surprising that chloroquine/hydroxychloroquine is concentrated within acidic organelles such as the endosome, Golgi vesicles, and the lysosomes, where the pH is low and most chloroquine/hydroxychloroquine molecules are positively charged. Chloroquine/hydroxychloroquine is extruded to the extracellular medium mostly by exocytosis.
and/or through the action of the multidrug resistance protein MRP-1, a cell surface drug transporter belonging to the ATP-binding cassette family, which also includes the more thoroughly studied P-glycoprotein.3–7

It is well established that weak bases, by increasing the pH of lysosomal and trans-Golgi network (TGN) vesicles, disrupt several enzymes including acid hydrolases and inhibit the post-translational modification of newly synthesised proteins. The chloroquine-mediated rise in endosomal pH modulates iron metabolism within human cells by impairing the endosomal release of iron from ferrated transferrin, thus decreasing the intracellular concentration of iron. This decrease in turn affects the function of several cellular enzymes involved in pathways leading to replication of cellular DNA and to expression of different genes.8–9

**General mechanisms of viral inhibition by chloroquine**

Chloroquine/hydroxychloroquine can impair the replication of several viruses by interacting with the endosome-mediated viral entry or the late stages of replication of enveloped viruses (figure 1).

**Endosome-mediated viral entry interaction**

Some viruses enter their target cells by endocytosis. This process targets the virus to the lysosomal compartment where the low pH, along with the action of enzymes, disrupts the viral particle, thus liberating the infectious nucleic acid and, in several cases, enzymes necessary for viral replication. Chloroquine has been shown to inhibit different viruses requiring a pH-dependent step for entry, such as the Borna disease virus,10 the minute virus of mice MVMp,11 and the avian leucosis virus.12 Of particular interest for human pathology is the report that chloroquine inhibits uncoating of the hepatitis A virus, thus blocking its entire replication cycle.13

**Replication of enveloped viruses interaction**

For some enveloped viruses, post-translational modification of the envelope glycoproteins occurs within the endoplasmic and TGN vesicles. This process involves proteases and glycosyl-transferases, some of which require a low pH. In line with the pH-dependence of these events, chloroquine was seen to inhibit budding of Mayaro virus particles,14 and to induce accumulation of non-infectious herpes simplex virus 1 particles in the TGN.15 Chloroquine also inhibits the replication of members of the Flaviviridae family by affecting the normal proteolytic processing of the flavivirus prM protein to M.16 As a result, viral infectivity is impaired. Finally, chloroquine induces the production of non-infectious retrovirus particles, as shown with the avian reticuloendotheliosis virus REV-A and with HIV-1.17 The mechanism of inhibition seems to be inhibition of glycosylation of the envelope glycoproteins, as will be discussed below.

**Effects of chloroquine on the immune system**

The accumulation of chloroquine/hydroxychloroquine in lymphocytes and macrophages results in anti-inflammatory properties, and has led to its clinical use in conditions such as rheumatoid arthritis, lupus erythematosus, and sarcoidosis, the last being characterised by an overproduction of tumour necrosis factor α (TNFα) by the alveolar macrophages.18 Chloroquine/hydroxychloroquine reduces the secretion of these proinflammatory cytokines and in particular TNFα, as shown in a murine macrophage cell line,19 and in primary cells

---

**Figure 2. Effects of chloroquine on the immune system.** TNFα is produced by activated monocytes/macrophages. Among its multiple functions it helps to activate resting monocytes and favours extravasation of neutrophils by opening tight junctions between human vascular endothelial cells and upregulating leucocyte adhesion molecules (LAM).20 Chloroquine diminishes TNFα production and downregulates the TNFα receptors 1 and 2 (TNFR) on the monocyte cell surface, which eventually results in decreased monocyte activation as well as decreased leucocyte extravasation. Red crosses mark the steps directly inhibited by chloroquine.
such as mouse peritoneal macrophages, human peripheral blood mononuclear cells, and human whole blood. Several mechanisms have been evoked to explain the chloroquine/hydroxychloroquine-induced inhibition of TNFα production by monocyte-macrophages: disruption of cellular iron homeostasis, inhibition of TNFα mRNA expression, inhibition at a pretranslational stage by a non-lysosomotropic mechanism, or at a post-translational stage by blocking the conversion from cell-associated pro-TNFα to a soluble mature form. Apart from inhibiting TNFα production by stimulated monocyte-macrophages, chloroquine also decreases the surface expression of TNFα receptors in human monocytic cell lines and, hence, the receptor-mediated TNFα signalling. The results of such an impairment of TNFα-mediated signalling are shown in figure 2.

Safety considerations

The studies reviewed here show that chloroquine/hydroxychloroquine has in-vitro antiviral effects and anti-inflammatory properties that may be of interest in those viral infections associated with inflammation and/or immune activation. Before analysing the potential effects of a drug on a disease, safety criteria have to be met, to estimate the risk/benefit ratio.

Chloroquine/hydroxychloroquine has a well-studied toxicity profile. The half-century-long use of this drug in the therapy of malaria demonstrates the safety of acute administration of chloroquine to human beings. The use of chloroquine/hydroxychloroquine in rheumatic diseases and for antimarial prophylaxis showed a low incidence of adverse events during chronic administration of this drug for periods of up to a few years. In these cases, the most serious toxic effect is a macular retinopathy, which depends on the cumulative dose rather than on the daily dose, and permanent damage may be prevented with regular visual monitoring during treatment. A recent study provided encouraging results on the safety of a high dosage of the drug (up to 500 mg of chloroquine base per day) even during pregnancy.

We conclude that chloroquine/hydroxychloroquine administration presents limited and well-preventable toxicity and may thus result in a low risk/benefit balance at least when it is used in life-threatening conditions.

Henceforth, we will discuss the potential usefulness of this old drug in the treatment of two infectious diseases posing a serious threat to public health in the era of globalisation—i.e., AIDS and severe acute respiratory syndrome (SARS). These diseases are both caused by enveloped RNA viruses, and share some clinical manifestations that are likely to be mediated by immune reactions of the host.

Effects on HIV infection

Anti-HIV effects of chloroquine

Under testing conditions intended to mimic as best as possible clinical situations, chloroquine/hydroxychloroquine is capable of inhibiting HIV in vitro. This ability was shown either by overloading the cells with high concentrations of chloroquine/hydroxychloroquine before the infection, so as to mimic the drug build-up taking place in the tissues of patients subject to chronic treatment, or by keeping HIV-infected cells under constant incubation with concentrations of chloroquine detected in whole blood of individuals chronically treated with this drug. The anti-HIV activity of chloroquine has been shown not only in cell line models, but also in peripheral blood lymphocytes and monocytes—i.e., cell culture models in which cellular uptake of chloroquine is closer to the conditions occurring in vivo. Under these conditions, it was possible to obtain levels of inhibition of viral replication above 90%. That hydroxychloroquine has some antiviral activity in vivo has been reported by two phase II clinical trials. The first trial was a small randomised, double-blind, placebo-controlled pilot study on 40 patients (20 patients per arm), of them being antiretroviral treatment-naive. Hydroxychloroquine administration for 8 weeks resulted in a mean 0.6 log reduction in plasma HIV-1 RNA copy numbers (p=0.02) as well as in a decrease in interleukin 6 concentrations, whereas placebo did not have any effects on both HIV-1 RNA and interleukin 6. The second trial was also a small randomised, double-blinded trial, comparing the effectiveness of chloroquine/hydroxychloroquine with that of zidovudine monotherapy for 16 weeks in 72 patients, 64 of whom being antiretroviral treatment-naive (35 in the chloroquine/hydroxychloroquine arm and 37 in the zidovudine arm). Hydroxychloroquine again significantly reduced the plasma HIV-1 RNA copy numbers/ml (baseline 39 456 [31 000]; post-treatment 16 434 [11 373]; mean log reduction 0.4; p=0.02), though less than zidovudine (baseline 42 709 [33 050]; post-treatment 11 228 [7459]; mean log reduction 0.6; p=0.01). Since eight of 37 people in the zidovudine group, but none of the 35 individuals in the hydroxychloroquine group, showed an increase in the HIV-1 RNA levels and in the cultured virus levels during therapy, these data are consistent with the hypothesis that resistance to hydroxychloroquine may not easily develop as opposed to the well-known development of resistance to monotherapy with other antiretrovirals such as zidovudine.

The results of larger clinical trials will be necessary for an accurate analysis of any possible discrepancies between the effects of chloroquine in vitro and in HIV-infected individuals.

Some of us have recently shown that chloroquine, at non-toxic, clinically achievable concentrations, has in-vitro activity against primary isolates belonging to different HIV-1 and HIV-2 clades. The mechanism of the anti-HIV effects of chloroquine/hydroxychloroquine is a reduction in the infectivity of newly produced virions (reviewed in Savarino et al). The antiviral effects of chloroquine are associated with the reduced production of the heavily glycosylated epitope 2G12, which is located on the gp120 envelope glycoprotein surface and is fundamental for virus infectivity. These effects are likely to be attributed to the increased pH in TGN, which impairs the function of glycosyl-transferases involved in the post-translational processing of the HIV glycoproteins. Therefore, HIV glycosylation may therefore represent a new target for antiretroviral therapy. As viral envelope glycosylation is mediated by cellular enzymes, its inhibition may explain the broad spectrum of the in-vitro anti-HIV activity of chloroquine against all major subtypes of HIV-1 and HIV-2. The effect of chloroquine/hydroxychloroquine on cellular rather than viral enzymes may also result in a low propensity to resistance development.
**Effects of chloroquine in combination with other antiretrovirals**

As chloroquine/hydroxychloroquine probably inhibits viral replication by a mechanism different from those of currently used antiretroviral drugs, its application has been studied in combination with other antiretroviral drugs. The use of chloroquine in combination with other antiretrovirals is theoretically supported by the observation that chloroquine also shows anti-HIV activity in vitro towards isolates from patients in therapeutic failure with a multidrug-resistant profile.

First, hydroxychloroquine has an additive in vitro anti-HIV effect to that of zidovudine. Second, chloroquine exerts in vitro an additive anti-HIV-1 effect on the combinations of hydroxyurea plus didanosine or hydroxyurea plus zidovudine in T-cell lines, monocytes, and primary T-cells. The didanosine/hydroxyurea/hydroxychloroquine combination, especially attractive for developing countries due to its low cost, was tested clinically in Singapore in an open study. Of the initial 22 patients who started the study, six were withdrawn due to non-compliance. In the remaining 16 patients, HIV-1 RNA plasma levels decreased by a mean of 1·3 log at week 12 and 48. In a smaller study, with didanosine/hydroxyurea/hydroxychloroquine, HIV-1 RNA remained lowered by a mean of 2·5 log after more than 96 weeks. These open pilot studies do not yet allow a determination of the contribution of chloroquine/hydroxychloroquine to the viral load drop. However, it can be concluded that the addition of chloroquine/hydroxychloroquine to hydroxyurea and didanosine is potentially safe, thus encouraging the design of larger studies with multiple arms.

**Prevention of HIV transmission via breastfeeding**

It is possible to hypothesise that chloroquine may find a potential application in prevention of mother-to-child transmission (MTCT) of HIV through breastfeeding, a problem still far from being solved in resource-poor countries. One of us reported a 243-fold accumulation of chloroquine in colostrum cells of Burkinabé mothers taking 100 mg of chloroquine daily and hypothesised that such a high degree of chloroquine accumulation in mammary cells actively replicating HIV-1 may allow a decrease in milk viral load and/or infectivity of milk and, hence, may lower the risk of breastfeeding-related transmission, which accounts for one-third to one-half of HIV-1 MTCTs. Therefore the CHARGE (Chloroquine Administration to Reduce HIV-1 Genome Exposure) study was set up, being a placebo-controlled pilot study in breastfeeding mothers (having received, together with their infant, peripartum nevirapine), that will assess whether daily chloroquine administration compared with placebo administration to the mother during the early months of breastfeeding may result in decreased HIV-1 RNA milk levels and/or decreased ex vivo infectivity of virions isolated from milk.

**Decrease of excessive immune activation**

The chloroquine/hydroxychloroquine-induced suppression of the synthesis of proinflammatory cytokines such as TNFα may be beneficial in decreasing the inappropriate immune activation characteristic of HIV infection. This may be particularly useful to people with HIV/AIDS in the developing world, who, probably due to concomitant infections, present higher levels of TNFα production and of immune activation than those from the developed world. Chloroquine/hydroxychloroquine should be studied, particularly in areas with high prevalence of HIV-1C, such as southern Africa. Indeed, when TNFα is used for in-vitro stimulation, the rate of transcriptional activation of HIV-1 is higher for HIV-1C than for HIV-1B and HIV-1 CRF_1AE. Such an enhanced capacity to respond to TNFα may be related to the extra NF-kappaB binding site(s) present in the long terminal repeat of the HIV-1C genome.

**Hypothesis: the case of SARS**

Based on the effects of chloroquine/hydroxychloroquine on several enveloped viruses and on immune activation, we raise the hypothesis that this drug might be of some use for the clinical management of SARS. At present, any attempt to treat this disease with known antiviral drugs—namely ribavirin and oseltamivir—has been inconclusive. Corticosteroids may be of some benefit in controlling the inflammatory response at the lung level but may also cause uncontrolled immunodepression resulting in pulmonary superinfection.

The causative agent of SARS has recently been described as a new coronavirus. Recent studies support the idea that coronaviridae infect their target cells by an endocytic pathway and that chloroquine might inhibit their replication. Cells infected with the human coronavirus...
HCoV-229E and treated with nocodazole (a microtubule-depolymerising agent that blocks transport from early to late endosomes) produced decreased amounts of HCoV-229E antigens. A result indicates that endosomal transport is needed for HCoV-229E infection. Cells treated with chloroquine expressed decreased amounts of HCoV-229E antigens. Preliminary data obtained from our group confirm these reports and show that chloroquine potently inhibits the replication of a canine coronavirus at therapeutically reachable concentrations (C Buonavoglia et al, University of Bari, Italy; unpublished). Although the SARS coronavirus is distinct with unique characteristics, it is tempting to ask whether chloroquine might affect SARS coronavirus replication as well.

The anti-inflammatory properties of chloroquine/hydroxychloroquine should also be considered. The clinical worsening of individuals with SARS in week 2 is apparently unrelated to uncontrolled SARS coronavirus replication but may be related to immunopathological damage. A model taking into account the role of proinflammatory cytokines could help interpret this event (figure 3). This view is derived from the effects of the porcine respiratory coronavirus (PRCV), which shares with the SARS coronavirus the ability to cause a disease with similar histopathological features and symptomatology. PRCV induces severe lung damage through immune-mediated mechanisms—ie, probably through an increase in the concentrations of proinflammatory cytokines such as TNFα and interleukin 6, whose role in inducing lung damage has been proved using adenoviral vectors in animal models. On these grounds, we think that the associations between TNFαs and interleukin 6 concentrations and disease severity should also be tested in stored samples from human patients with SARS. If confirmatory results are obtained, then, it would be reasonable to consider chloroquine/hydroxychloroquine to suppress TNFαs and interleukin 6 production. For this purpose, efforts to develop an animal model for SARS would be welcome. Such a model would help to clarify the immune-mediated component of the symptoms of the disease as well as in testing of chloroquine and other immunomodulatory drugs. These studies could also lay the groundwork for the suggestion that chloroquine be considered for the treatment of other viral infections which involve immunopathology.

Conclusions

At present it is difficult to answer the question of whether old chloroquine will be able to live a "second youth". Due to its main effect—ie, raising endosomal pH—the drug has an exceptionally broad spectrum of antimicrobial activity that could be exploited in many infections. Results obtained in the prophylaxis of Q fever indicate that chloroquine/hydroxychloroquine can be successfully used in the clinical management of infections other than malaria. As regards viral diseases, what is clear is that the drug has antiviral and immunomodulatory effects that warrant particular consideration.

The effects on HIV infection are the best studied among the antiviral effects of chloroquine/hydroxychloroquine and are being tested in clinical trials. The anti-HIV effect of chloroquine/hydroxychloroquine is modest by itself but is, at least in vitro, additive or synergistic when combined with selected antiretrovirals. These in-vitro results warrant in-vivo confirmation in HIV-positive individuals by comparing the long-term antiviral effect of highly active antiretroviral therapy regimens with and without chloroquine or hydroxychloroquine. If such studies provide encouraging results, they may lead to a strategy whereby co-administration of chloroquine/hydroxychloroquine allows lower doses of antiretrovirals, lessening cost and possibly toxicity. Cost-lessening would of course be particularly welcome in developing countries. Moreover, the potential ability of chloroquine to inhibit the replication of drug-resistant viral isolates could be important in the treatment of drug-experienced HIV-positive patients who have developed multiple resistance to antiretroviral drugs and thus have limited therapeutic options. In the developing countries where malaria is endemic, the concomitant administration of chloroquine/hydroxychloroquine to a highly active antiretroviral therapy regimen may result (at least where P falciparum is still susceptible to chloroquine) in a decreased incidence of malaria episodes that have adverse effects in HIV-infected people, especially during pregnancy. Moreover, the anti-inflammatory properties of chloroquine may temper the noxious immune hyperactivation that is characteristic of HIV/AIDS.

Due to its broad spectrum of antiviral activity as well as to its suppressive effects on the production/release of TNFαs and interleukin 6, chloroquine/hydroxychloroquine may also find a place in the treatment of other viral infections characterised by symptoms associated with inflammatory processes and/or immune-hyperactivation. We believe that further study should be devoted to the inhibitory effects of chloroquine on the infectivity of flaviviruses, as one of the members of this family, the hepatitis C virus, is of great importance for human pathology and often co-infects individuals with HIV-1. Flaviviridae also include several arthropod-borne viruses such as the yellow fever virus and the West Nile virus, which has recently caused an epidemic in North America.

Finally, we want to share with the scientific community the speculative hypothesis that chloroquine/hydroxychloroquine, due to its antiviral and anti-inflammatory effects, may also be exploited in many infections that block transport from early to late endosomes.

Search strategy and selection criteria

We did literature reviews using relevant Medline search terms, in various combinations—"chloroquine", "virus", "retrovirus", "TNFα", "cytokines", "endothelium", "macrophages", "HIV", "SARS", "NF-kappa B", "coronavirus", "proinflammatory cytokines", and "ARDS"—screened articles for relevance, and reviewed references. Because of space restrictions we (1) cited review articles in place of original manuscripts where possible, (2) excluded those articles whose content was not in line with the bulk of the published information without giving convincing explanations, and (3) ranked the articles on the basis of relevance, date of publication, and journal impact factor. We also searched the internet for relevant web pages, discarded those edited by people/institutions not directly involved in research, and reviewed references. References are not intended to provide a comprehensive listing, but were chosen to best highlight the critical issues.
properties, may have some effect on SARS. We emphasise the need to testing in cell cultures infected with SARS the effects of chloroquine, as well as those of other substances possessing in-vitro activity against members of the coronaviridae family. We should remember other substances possessing in-vitro activity against properties, may have some effect on SARS. We emphasise.

References

1 Canadian rheumatological association. Canadian J Rheumatol 2000; 27: 2919–21.

2 Saravia GN, Semple P, Kerber K, Boearett JR. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001; 20: 131–35.

3 Boearett JR, Pitter, S, Kerber K. The potential place of chloroquine in the treatment of HIV-1 infected patients. J Clin Virol 2001; 20: 137–40.

4 Ohkuma S, Poole B. Cytoplastic vacuolation of mouse peritoneal macrophages and the uptake into rous sarcoma virus. J Cell Biol 1981; 90: 656–64.

5 Pozancos OP, Motka K, Adler E, Gicho D, Bosia A. Movements of vesicles in rous sarcoma virus infected cells. J Cell Biol 1988; 106: 212–17.

6 Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinine-based drugs. Biochem Pharmacol 2000; 59: 1245–52.

7 Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP). possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol 1998; 56: 733–42.

8 Byrd TF, Horwitz M. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 1991; 88: 55–57.

9 Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR. Chloroquine inhibits the infectivity by chloroquine. Inhibition of human immunodeficiency virus type 1 replication by chloroquine in human peripheral blood mononuclear cells. J Virol 1993; 67: 91–98.

10 Gonzalez-Dunia D, Cubitt A, de la Torre JC. Endocytosis is a critical step in entry of subgroup B retrovirus. Mol Biol Cell 1994; 5: 235–41.

11 Bernstein HN. Oxal safety of hydroxychloroquine. Ann Pharmacother 1991; 25: 291–93.

12 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

13 Vezmar M, Georges E. Chloroquine inhibits the intracellular multiplication of L. pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 1991; 88: 55–57.

14 Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR. Chloroquine inhibits the infectivity by chloroquine. Inhibition of human immunodeficiency virus type 1 replication by chloroquine in human peripheral blood mononuclear cells. J Virol 1993; 67: 91–98.

15 Byrd TF, Horwitz MA. Chloroquine inhibits the intracellular multiplication of L. pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 1991; 88: 55–57.

16 Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR. Chloroquine inhibits the infectivity by chloroquine. Inhibition of human immunodeficiency virus type 1 replication by chloroquine in human peripheral blood mononuclear cells. J Virol 1993; 67: 91–98.

17 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

18 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

19 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

20 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

21 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

22 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

23 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

24 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

25 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

26 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

27 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

28 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

29 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

30 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

31 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

32 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

33 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

34 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

35 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

36 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

37 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

38 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

39 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

40 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

41 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

42 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

43 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

44 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

45 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

46 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

47 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

48 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

49 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

50 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

51 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

52 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

53 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

54 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

55 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

56 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

57 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

58 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

59 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

60 fenomeno de la enfermedad. JAMA 2003; 289: 212–23.

For personal use. Only reproduce with permission from The Lancet.